 "Aurobindo Unit 7 gets USFDA observations")
Don't want to miss the best from Business Standard?
Hyderabad-based Aurobindo Pharma Limited today said two of its manufacturing facilities, Unit 3 and Unit 7 underwent pre-approval inspection by US Food and Drug Administration.
In a reply to stock exchanges over a related news report, the company stated that there were no Form 483 observations issued for Unit 3 but there were some for the latter.
"With regard to Unit 7 there were certain observations," Aurobindo said. "The company is appropriately responding and this has no perceived impact on the operations and exports from the said facility". A spokesperson, when contacted. stated that these units underwent inspection by the US FDA last week.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app